Table 1.
Detailed clinicopathological data of the BC patients and healthy controls.
| Healthy Donors | BC Patients | |
|---|---|---|
| Patients (n) | 18 | 72 |
| Median age at diagnosis (min–max) |
57 (46–65) |
59 (30–93) |
| Median tumor size (mm) (min–max) |
− | 26 (0.3–67) |
| Molecular subtype * (%) | ||
| Luminal A | − | 39 (54.2) |
| Luminal B | − | 29 (40.3) |
| HER2-enriched | − | 2 (2.8) |
| Basal-like/TNBC | − | 2 (2.8) |
| Histological type (%) | ||
| Invasive ductal carcinoma | − | 53 (73.6) |
| Invasive lobular carcinoma | − | 14 (19.4) |
| Mixed-type carcinoma | − | 2 (2.8) |
| Special subtype | − | 3 (4.2) |
| Grade (%) | ||
| G1 | − | 1 (1.4) |
| G2 | − | 42 (58.3) |
| G3 | − | 28 (38.9) |
| Gx | − | 1 (1.4) |
| T stage (%) | ||
| T1 | − | 31 (43.1) |
| T2 | − | 19 (26.4) |
| T3 | − | 14 (19.4) |
| T4 | − | 8 (11.1) |
| N stage (%) | ||
| N0 | − | 32 (44.4) |
| N1 | − | 15 (20.8) |
| N2 | − | 8 (11.1) |
| N3 | − | 8 (11.1) |
| Nx | − | 9 (12.5) |
| M stage (%) | ||
| M0 | − | 51 (70.8) |
| M1 | − | 18 (25.0) |
| Mx | − | 3 (4.2) |
| Menopause Status (%) | ||
| Pre | − | 16.7 |
| Post | − | 83.3 |
* As determined by immunohistochemistry analysis. Abbreviations: HER2—human epidermal growth factor receptor 2; TBNC—triple-negative breast cancer.